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1  | INTRODUC TION
Diabetes is a set of metabolic diseases recognized by high blood glucose 
levels arising from complications in insulin production, insulin use, or 
both (Alavi et al., 2020; Fan, 2017). Regarding the information obtained 
from International Diabetes Federation in 2015, nearly 415 million 
people suffered from diabetes worldwide, and this is expected to be 
more than 640 million by the year 2040 (Papatheodorou et al., 2018). 
Also, according to the National Diabetes Survey of Pakistan, 26.3% 
of adults (≥20) were diabetic in 2016–2017 that was equal to 27.4 
million people (Basit et al., 2020). Diabetes is a complex and chronic 
disease that affects many organs of the body. It increases the risk of 
various disorders, such as retinopathy, neuropathy, nephropathy, and 
cardiovascular disease (Alavi, et al., 2019; Preguiça et al., 2020). These 
disorders are a remarkable cause of increased morbidity and mortality 
among diabetic people (Eid et al., 2019).
Milk plays a significant role in nutrition and health due to having a 
unique composition of proteins, vitamins, carbohydrates, and minerals. 
Camel milk is a valuable and common source of nutrition in many coun-
tries, in which it is different not only in composition but also in function 
(Alabdulkarim, 2012). It is a rich source of immunoglobulins (G and A), 
vitamins [A, B2, C (highest), and E], and minerals (Na, K, Fe, Cu, Zn, and 
Mg) while sugar, proteins, and cholesterol are not present in high con-
centration in camel milk (Hammam, 2019; Mullaicharam, 2014). Also, 
it contains less quantity of short-chain fatty acid carotene and a high 
concentration of long-chain fatty acids (Al-Nasseri et al., 2019). Camel 
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Camel milk is a valuable source of nutrition with a wide range of therapeutic ef-
fects. Its unique composition helps to regulate the blood glucose level. The current 
study is aimed to evaluate the antidiabetic and hepatoprotective effects, as well as 
lipid profile restoration of camel milk in the diabetic mouse model. This innovative 
study evaluates the therapeutic effects of camel milk in diabetic mice by simultane-
ous measurement of blood glucose, HbA1c, ALT, AST, TG, cholesterol, and histo-
pathological studies. The results showed that camel milk has significantly reduced 
blood glucose, HbA1c (p < .001), aspartate transaminase (AST), alanine transaminase 
(ALT) (p < .01), triglyceride (TG), and cholesterol (p < .01), compared to that in the 
diabetic control group. Also, the therapeutic effects of camel milk were completely 
comparable with the antidiabetic drug glibenclamide. The results of this study sug-
gest that camel milk could be used as a proper alternative treatment regimen for 
diabetes therapy.
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milk has high concentrations of antimicrobial agents. The concentra-
tion of lactoferrins in camel milk is about twofold to sixfold higher as 
compared to that in cow milk (Niaz et al., 2019). Comparing human and 
camel milk, both compositions are almost the same as they are free of 
β-lactoglobulin, while α-lactalbumin is the major protein in both (Merin 
et al., 2001). Also, as both are rich in β-casein, camel milk can be di-
gested easily without any allergic effect (Gizachew et al., 2014).
The therapeutic effects of camel milk are known in different 
parts of the world due to the presence of bioactive agents in the 
milk. It has been used for the treatment of different diseases, such 
as dropsy, jaundice, tuberculosis, kala-azar (Ali & Al-Attar, 2020) and 
anemia (Abdurahman, 2018). Furthermore, it has been demonstrated 
that camel milk is very effective in the treatment of liver disorders 
to normalize their functions (Darwish et al., 2012). Also, anticancer 
(Yang et al., 2019), antiallergic (Gizachew et al., 2014), and antidia-
betic effects (Hammam, 2019) of camel milk have been proved. In 
addition, it is highly digestible with antioxidative capability (Ugwu 
et al., 2019). In different regions of Asia, the Middle East, and Africa, 
camel milk is used for the treatment of diabetes mellitus due to the 
therapeutic effect of its immunoglobulins on β cell of Langerhans 
islets (Agrawal et al., 2007).
The present study is aimed to evaluate the antidiabetic and hepa-
toprotective effects of camel milk in mice. In this regard, mouse dia-
betic model was established, and their serum glucose level, HbA1c, 
total cholesterol, and triglycerides were measured. Also, the histo-
pathological studies were performed in the heart, liver, and pancreas.
2  | MATERIAL S AND METHODS
2.1 | Chemicals
Streptozotocin (purchased from Sigma-Aldrich), sodium citrate, glib-
enclamide, and ethylenediaminetetraacetic acid (EDTA) were of ana-
lytical reagent grade purity were used.
2.2 | Animals
Healthy male and female mice were obtained from the National 
Veterinary Laboratory, Islamabad, Pakistan. They were kept in 
friendly house conditions suitable for animal survival with a temper-
ature of 25 ± 2°C and humidity. Twelve-hour light and dark cycles 
were provided. Animals had free access to “water ad libitum” and 
were provided with a standard animal diet. All animal experiments 
were approved by the ethics committee of PMAS-Arid Agriculture 
University, Rawalpindi, Pakistan.
2.3 | Collection and analysis of camel milk
Fresh camel milk was collected from the herd of camels on alter-
nating days and was kept in cool and sealed containers for further 
analysis in the laboratory of University Institute of Biochemistry 
and Biotechnology, PMAS—Arid Agricultural University, Rawalpindi, 
Pakistan.
2.4 | Evaluation of antidiabetic activity
2.4.1 | Experimental design
Sixty animals were divided into five groups, each having 12 animals 
(Ebaid et al., 2013).
Group 1: No treatment
Group 2: Camel milk
Group 3: Diabetic mice
Group 4: Diabetic mice + raw camel milk
Group 5: Diabetic mice + glibenclamide
2.4.2 | Experimental induction of diabetes
The animals in groups 3, 4, and 5 were induced diabetes after 24 hr 
fasting by a single injection of streptozotocin (40 mg/kg body weight) 
given intraperitoneally (Hu et al., 2017). Streptozotocin is a selective 
beta-cell genotoxicant, and its single high dose administration induces 
a quick onset of diabetes by producing a sufficient amount of DNA ad-
ducts, leading to over activation of polyadenosine diphosphate ribose 
synthetase in the base excision repair pathway (Burns & Gold, 2007). 
Streptozotocin was prepared in 0.1 M citrate buffer (pH 4.5). The ani-
mals were fed 20% glucose solution after injection for one night to 
avoid hypoglycemic death of animals due to the injections. The animals 
which were given injections of Streptozotocin showed glycosuria that 
was determined by Benedict's test (Ramalingam et al., 2020). Diabetes 
was confirmed by measuring the concentration of blood glucose level 
96 hr after drug administration. Animals having more than 240 mg/dl 
of blood glucose level were considered diabetic to be used in this study.
2.4.3 | Treatment
a. Camel milk
The mice in groups 2 and 4 received fresh camel milk daily 
(83 ml/kg) for 7 weeks (Mansour et al., 2017). The mice were given 
free access to camel milk other than their regular feed. Camel milk 
was replaced in feeding bottles daily.
a. Antidiabetic drug
The diabetic mice in group 5 were given antidiabetic drug glib-
enclamide to compare its effect with camel milk. The drug was pre-
pared in distilled water and given in a dose of 600 µg/kg body weight 
to each mouse orally in the morning (Zangeneh et al., 2018).
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2.5 | Collection and processing of blood and 
tissue samples
After treatment for 7 weeks, the mice were etherized, and blood 
samples were taken from their heart in 2 tubes. In tube 1, the blood 
was centrifuged to obtain serum, and in tube 2, the blood was mixed 
with EDTA to obtain plasma. Next, mice were sacrificed, and their 
heart, liver, and pancreas were removed. The collected tissues were 
instantly preserved in 10% formalin for histopathological studies by 
using hematoxylin and eosin (H & E) staining (Ghaferi, Amari, et al., 
2020). For this purpose, the successive sections of paraffin-embed-
ded tissues were prepared (Alavi, et al., 2019). The sections were 
then placed on glass slides, deparaffinized, rehydrated, and finally 
stained with H & E (Al Harthi et al., 2019; Ghaferi et al., 2020; Sale 
et al., 2020). Serum glucose level was quantified by using a reagent 
kit (Adaltis) according to the method described by Trinder (1969). 
Total cholesterol level and triglycerides (TG) were estimated (Aloud 
et al., 2018; Benkhaled et al., 2020) by using reagent kits (Chengxinde 
reagent company). HbA1c and liver enzymes (ALT and AST) were es-
timated and verified with kits (Ghaferi, Asadollahzadeh, et al., 2020; 
Lv et al., 2020) by using an HbA1c test kit (Beijing Wantai Dro Co., 
Ltd.) and AST and ALT commercial kits (Jiancheng Bioengineering 
Institute).
3  | RESULTS AND DISCUSSION
In the present study, the efficacy of camel milk to treat diabetic 
mice was evaluated. For this purpose, diabetic animal model was 
established through the intraperitoneal injection of antibiotic 
streptozotocin.
The blood glucose evaluation confirmed that all mice got dia-
betes. Diabetes is a risk factor for the development of liver disor-
ders, such as fibrosis and nonalcoholic fatty liver disease (Brouha 
et al., 2018). Therefore, in addition to blood glucose and HbA1c 
levels, serum concentrations of liver biomarkers, including ALT and 
AST, were measured. Also, dyslipidemia is a diabetes consequence 
characterized by hypertriglyceridemia and elevated LDL cholesterol 
(Lazarte & Hegele, 2020); therefore, serum TG and total cholesterol 
were measured.
Figure 1 shows that the mean blood glucose in diabetic mice is 
346 mg/dl, and this value in diabetic mice fed by camel milk is de-
creased to 140 mg/dl, which is not significantly different from the 
diabetic animal receiving glibenclamide (blood glucose of 125 mg/
dl). Also, the pattern changes in HbA1c in different groups of mice 
are in accordance with the blood glucose levels. The results of the 
present study are in accordance with the above-mentioned studies 
that camel milk statistically decreased the blood glucose and HbA1c 
concentrations in diabetic mice (p < .001).
A few studies evaluated the antidiabetic effects of camel milk (R. 
Agrawal et al., 2004; Hamad et al., 2011; Khan et al., 2013). Agrawal 
et al. (2004) evaluated the potency of camel milk to glycemic control 
in diabetic rats that diabetic animals which received camel milk had 
considerably lower blood glucose levels compared with the control 
diabetic animal. Hamad et al. (2011) investigated the antidiabetic ef-
fects of camel milk compared with cow and buffalo milk on diabetic 
Sprague-Dawley rats proved that camel milk had higher hypoglyce-
mic effects (49%) compared with cow and buffalo milk (11%).
Results of Table 1 confirmed the potency of camel milk to re-
store the activity of ALT and AST enzymes as associated with hepa-
tocellular biomarkers. These protective effects of camel milk could 
F I G U R E  1   Mean blood glucose 
(Glu) and HbA1c concentrations in 
different groups of mice treated with 
the preparations of camel milk and 
glibenclamide
TA B L E  1   The effects of camel milk and the drug (glibenclamide) 
on the concentrations of ALT and AST in different groups of 
diabetic and nondiabetic mice
Groups
Biomarker
ALT (U/L) AST (U/L)
No treatment 59.8 ± 1.15 91.0 ± 2.55
Milk 61.7 ± 0.76 93.4 ± 2.49
Diabetic 114 ± 3.83 144 ± 2.88
Diabetic + Drug 67.5 ± 3.39 103 ± 2.59
Diabetic + milk 77.8 ± 3.03 122 ± 5.59
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result from its antioxidant activity and probable chelating effects 
on toxicants (Al-Humaid et al., 2010). Hamad et al. (2011) and Khan 
et al. (2013), assessed hepatoprotective effects of camel milk in the 
diabetic animal model. Hamad et al. (2011) evaluated the hepatopro-
tective effects in diabetic rats and observed an improvement in the 
activities of ALT and AST by 41% and 38%, respectively, compared 
with the control group. Khan et al. (2013) assessed hepatoprotective 
effects in diabetic rats, and the results demonstrated that camel milk 
approximately restored the functionality of ALT (70 U/L) and AST 
(98 U/L) compared with the healthy control group (ALT and AST of 
75 and 45 U/L, respectively).
The results of the current study (Figure 2) demonstrated that 
camel milk significantly restored the functionality of ALT and AST 
enzymes compared with the control diabetic mice (p < .001). While 
ALT and AST values in diabetic mice were 114 and 144 U/L, respec-
tively. The mean values in diabetic mice after camel milk treatment 
were 78 and 122 U/L. Also, ALT and AST concentrations in diabetic 
mice treated with glibenclamide were 67 and 102 U/L, respectively, 
indicating the comparable efficacy of camel milk with glibenclamide 
in restoring the functionality of ALT and AST.
The high levels of vitamins (A, B2, and C, E act as an antiox-
idants) are present in camel milk which are useful in preventing 
tissue damage by toxic materials, such as streptozotocin (Sadek 
et al., 2016). Furthermore, camel milk contains a high level of zinc, 
a trace element required for living organisms (Sadek et al., 2016). 
There are more than 300 enzymes, which required Zn for their 
activity and a relationship with many body enzymes (Marreiro 
et al., 2017).
The results of the present study (Figure 3) showed that camel 
milk was effective in reducing the blood TG and cholesterol con-
centrations by 26% and 22%, respectively, compared with the con-
trol diabetic mice (p < .01). More importantly, the efficacy of camel 
milk in the normalization of the blood TG and cholesterol in diabetic 
mice was comparable to the diabetic mice given antidiabetic drug 
glibenclamide. While the blood TG and cholesterol concentrations 
in diabetic mice which received camel milk were 149.8 and 186 mg/
dl, respectively, the mean values in diabetic mice which received 
glibenclamide were 146 and 169 mg/dl, respectively. These find-
ings support the idea that camel milk can be used as an alternative 
regimen for diabetes treatment, although various studies evalu-
ated the antidiabetic effect of camel milk in in vivo environment 
(Agrawal et al., 2020; Aqib et al., 2019; Korish et al., 2020).
Khan et al. (2013) and Sboui et al. (2010) evaluated the thera-
peutic effects of camel milk on the lipid profile of diabetic animals. 
Khan et al. (2013) showed that camel milk restored the lipid profile 
to near control levels. The results demonstrated that camel milk 
F I G U R E  3   Mean TG and cholesterol 
concentrations in diabetic mice received 
camel milk and glibenclamide
F I G U R E  2   Mean ALT and AST 
concentrations in diabetic mice received 
camel milk and glibenclamide
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F I G U R E  4   Histopathological evaluation of the pancreas by using H & E staining in different groups of mice. As the figure shows, there 
were no considerable pathological changes in the pancreases of diabetic mice received glibenclamide drug (d) and camel milk (e) and were 
significantly less than the pathological changes (size shrinkage, reducing the number of the islets, and beta-cell destruction) observed in the 
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F I G U R E  5   Histopathological evaluation of the heart in different groups of mice by using H & E staining. As the figure shows, there were 
no considerable pathological changes in the hearts of diabetic mice received glibenclamide drug (d) and camel milk (e) and were significantly 
less than the pathological changes (confused cellular nuclei and degenerative changes) in the heart of control diabetic mice not received 
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F I G U R E  6   Histopathological evaluation of liver by using H & E staining in different groups of mice. As the figure shows, the pathological 
changes in the liver of diabetic mice received glibenclamide drug (d) and camel milk (e) were approximately comparable and considerably less 
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decreased the blood cholesterol and TG concentrations by 34% and 
35%, respectively, in diabetic rats. In addition, camel milk decreased 
the blood cholesterol concentration by 26% in diabetic dogs, with 
small decrease in blood TG concentration (Sboui et al., 2010).
The present study is the first report which evaluated the factors 
of blood glucose, HbA1c, total cholesterol, triglycerides, ALT, and 
AST simultaneously.
3.1 | Histopathological findings
Normal histological structure of the pancreas with normal-sized is-
lets (Figure 4) was observed in normal mice, while size shrinkage, 
decrease in the number of the islets, and destruction of beta cells 
were observed in control diabetic mice.
Streptozotocin specifically affects the pancreatic insulin-se-
creting β-cells and induces the increase in the reactive oxygen 
species (ROS) level in the pancreas, liver, and relative tissues. 
Increasing ROS levels cause tissue damages and increased lipid 
peroxidation, which results in the production of free radicals; as a 
result, the oxidative damage of polyunsaturated fatty acids occurs. 
In physiological conditions, the tissue concentration of lipid per-
oxides is low (Gayathri & Kannabiran, 2010). Bolkent et al. (2006) 
demonstrated that the plasma concentration of lipid peroxides 
was elevated in diabetic rats. Increased plasma concentration of 
lipid peroxides in diabetic rats and lipid peroxide-mediated dam-
age is regarded as one of the characteristic features of chronic dia-
betes (Bolkent et al., 2006). Tissue damage, due to lipid peroxides, 
can contribute to the development of both type 1 and 2 diabetes 
(Lenzen, 2008). The intensity of pathological changes was reached 
to a minimum in diabetic mice which received camel milk or glib-
enclamide. Also, a typical histological structure of the heart was 
observed in normal mice, whereas pathological changes, including 
confused cellular nuclei and degenerative changes, were observed 
in control diabetic mice. However, the pathological changes were 
reached to a minimum in diabetic mice treated with antidiabetic 
drug and camel milk (Figure 5). Liver showed a usual histological 
structure in normal mice, while hypertrophic hepatocytes along 
with degenerative changes were observed in the diabetic control 
mice (Figure 6). The pathological changes in diabetic mice were 
treated with camel milk or glibenclamide found less compared 
with the untreated diabetic mice (Figure 6). Overall, the results of 
histopathological findings were in accordance with the results of 
blood glucose, HbA1c, ALT, AST, TG, and cholesterol levels show 
that camel milk decreased the histopathological lesions compared 
with the control diabetic group, and the pathological changes were 
comparable with diabetic mice which received glibenclamide.
4  | CONCLUSION
In this study, the efficacy of camel milk in the treatment of diabetic 
mice was evaluated and confirmed. Also, the potency of camel milk 
to restore the activity of hepatocyte enzymes ALT and AST was 
evaluated. The results demonstrated that camel milk was approxi-
mately effective as much as glibenclamide. In addition, camel milk 
was efficacious nearly as much as glibenclamide to normalize blood 
TG and cholesterol concentrations. The results of the present study 
suggest that camel milk, as a natural and safe product, can be used 
as an alternative treatment regimen in diabetes therapy.
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